What is it about?
In this work we have identified a previously undefined immune cell which is involved in anti-tumour immunity. Tumour derived lactate can induce PD-1 (checkpoint receptor) on these cells in cancer. Using blocking antibodies or genetic knockdown, we have shown that these cells can become activated and produce anti-tumour cytokines. hence these may be the first immune cell to be activated within the context of checkpoint inhibitor therapy.
Featured Image
Why is it important?
The success rate of checkpoint therapy is around 30% and we are still working on stratifying cancer patients for better outcomes. This work proposes that the frequency of these immune cells (Tbet+ILCs) can determine therapy efficacy.
Read the Original
This page is a summary of: Programmed cell death-1 receptor-mediated regulation of Tbet
+
NK1.1
−
innate lymphoid cells within the tumor microenvironment, Proceedings of the National Academy of Sciences, April 2023, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2216587120.
You can read the full text:
Contributors
The following have contributed to this page
